A detailed history of Price T Rowe Associates Inc transactions in Bicycle Therapeutics PLC stock. As of the latest transaction made, Price T Rowe Associates Inc holds 1,722,040 shares of BCYC stock, worth $25.3 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,722,040
Previous 798,501 115.66%
Holding current value
$25.3 Million
Previous $16.2 Million 141.12%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$19.58 - $27.24 $18.1 Million - $25.2 Million
923,539 Added 115.66%
1,722,040 $39 Million
Q2 2024

Aug 14, 2024

BUY
$20.02 - $24.69 $7.95 Million - $9.8 Million
396,855 Added 98.81%
798,501 $16.2 Million
Q1 2024

May 15, 2024

BUY
$16.75 - $26.1 $2.09 Million - $3.26 Million
124,809 Added 45.08%
401,646 $10 Million
Q4 2023

Feb 14, 2024

SELL
$13.29 - $22.2 $4.2 Million - $7.02 Million
-316,216 Reduced 53.32%
276,837 $5.01 Million
Q3 2023

Nov 14, 2023

BUY
$19.9 - $26.25 $5.89 Million - $7.76 Million
295,768 Added 99.49%
593,053 $11.9 Million
Q2 2023

Aug 14, 2023

SELL
$18.95 - $28.67 $393,989 - $596,077
-20,791 Reduced 6.54%
297,285 $7.59 Million
Q1 2023

May 15, 2023

SELL
$20.02 - $31.37 $413,553 - $648,010
-20,657 Reduced 6.1%
318,076 $6.77 Million
Q4 2022

Feb 14, 2023

SELL
$20.37 - $32.9 $1.6 Million - $2.59 Million
-78,607 Reduced 18.84%
338,733 $10 Million
Q3 2022

Nov 14, 2022

SELL
$17.49 - $28.44 $68,578 - $111,513
-3,921 Reduced 0.93%
417,340 $9.71 Million
Q2 2022

Aug 15, 2022

SELL
$12.95 - $46.99 $3.43 Million - $12.4 Million
-264,615 Reduced 38.58%
421,261 $7.07 Million
Q1 2022

May 16, 2022

SELL
$40.12 - $59.5 $4.42 Million - $6.55 Million
-110,138 Reduced 13.84%
685,876 $30.1 Million
Q4 2021

Feb 14, 2022

BUY
$41.7 - $61.14 $33.2 Million - $48.7 Million
796,014 New
796,014 $48.5 Million

Others Institutions Holding BCYC

About BICYCLE THERAPEUTICS plc


  • Ticker BCYC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 29,676,100
  • Market Cap $436M
  • Description
  • Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. Its lead product candidate is BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease. The co...
More about BCYC
Track This Portfolio

Track Price T Rowe Associates Inc Portfolio

Follow Price T Rowe Associates Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Price T Rowe Associates Inc , based on Form 13F filings with the SEC.

News

Stay updated on Price T Rowe Associates Inc with notifications on news.